We are here to make a difference.
Abdera is here to walk beside you through every step of your cancer journey.
Whether you’ve just been diagnosed, are undergoing treatment, or are in recovery, you are not alone. Abdera is purpose-built to attack cancer and inspire hope.
We are leaders in one of the most innovative areas in cancer therapy: targeted radiopharmaceuticals. We are leveraging our advanced antibody engineering platform to take radiopharmaceuticals to the next level – with the goal of providing groundbreaking new cancer treatments and delivering them to those who matter most: people living with cancer.
Our Clinical Trials
ABD-147 is an experimental targeted radiopharmaceutical designed to deliver Actinium-225, a potent radioisotope, to SCLC and LCNEC tumors that express the protein delta-like ligand three (DLL3).
DLL3 is found on the tumor cell surface of neuroendocrine cancers like SCLC and LCNEC, but it is not expressed on the cell surface of healthy cells, making it an ideal target for therapies designed to treat patients living with these conditions.
Abdera Therapeutics is testing ABD-147 in small cell lung cancer (SCLC) patients who have been failed by platinum chemotherapies. People with large cell neuroendocrine (LCNEC) lung tumors may also qualify for the clinical trial. This Phase 1 study of ABD-147 is designed to result in information about the best dose for further development.
Abdera’s Policy on Expanded Access to 225Ac-ABD147: Abdera-developed therapies are investigational and have not been approved as safe and effective by the U.S. Food and Drug Administration (FDA). At this time, Abdera does not offer an Expanded Access program for 225Ac-ABD147. We will continue to evaluate our policy on an ongoing basis and will update this website should changes occur.
For additional information, please visit clinicaltrials.gov/study/NCT06736418.